Compositions and methods involving an essential
View Patent ↗This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of a Staphylococcus aureus ( S. aureus ) DnaI related protein, as well as its variants. The invention also relates to a specific interaction between the S. aureus DnaI related protein or specific regions thereof, and a growth-inhibitory protein encoded by the S. aureus bacteriophage 77 genome. The phage open reading frame (ORF) product interacts with amino acids 150–313 of S. aureus DnaI polypeptide, and the invention relates to the use of this interaction target site as the basis of drug screening assays. Accordingly, the invention provides a method for the inhibition of bacterial growth, and the treatment of bacterial infection via the inhibition of DnaI.
1. A method for inhibiting bacterial growth, comprising contacting bacteria in vitro with an amount of an inhibitor effective to reduce a DnaI activity of a polypeptide comprising the amino acid sequence of SEQ ID NO: 16, wherein said inhibitor inhibits bacterial growth.
2. The method of claim 1 wherein said inhibitor is selected from the group consisting of a small molecule, a peptidomimetic compound, and a bacterial growth inhibitory bacteriophage polypeptide.
3. The method of claim 1 wherein said inhibitor is a peptide synthesized by a recombinant expression system and purified, or artificially synthesized.
4. A method for inhibiting bacterial growth, comprising contacting bacteria in vitro with an effective amount of an inhibitor that decreases a DnaI activity of a polypeptide selected from the group consisting of:
a polypeptide comprising the amino acid sequence of SEQ ID NO: 2;
a polypeptide comprising the amino acid sequence of SEQ ID NO: 16; and
a polypeptide comprising the amino acid sequence of SEQ ID NO: 18,
wherein said inhibitor inhibits bacterial growth.
5. The method of claim 4 , wherein said inhibitor is selected from the group consisting of a small molecule, a peptidomimetic compound, and a bacterial growth inhibitory bacteriophage polypeptide.
6. The method of claim 4 , wherein said an inhibitor is a peptide synthesized by a recombinant expression system and purified, or artificially synthesized.
7. A method for inhibiting bacterial growth, comprising contacting a bacteria in vitro with an amount of an inhibitor effective to decrease the activity of a polypeptide selected from the group consisting of
a DnaI polypeptide comprising at least 50% identity to the amino acid sequence of SEQ IID NO: 2;
a DnaI polypeptide comprising fragments of the amino acid of SEQ ID NO: 2;
wherein said polypeptide has an activity selected from the group consisting of:
a) directly interacting with bacteriophage 77 ORF 104 protein or a DnaI-binding fragment thereof in a manner that results in at least 10 fold reduction of 3 H-thymidine incorporation in a bacterial DNA replication assay relative to 3 H-thymidine incorporation in an assay lacking bacteriophage 77 ORF 104 protein or a DnaI-binding fragment thereof;
b) directly interacting with bacteriophage 77 ORF 104 protein or a DnaI-binding fragment thereof in a manner that results in at least 10% inhibition of plasmid replication by bacteriophage 77 ORF 104 protein or a DnaI-binding fragment in a plasmid replication assay; and
c) aiding in the loading of S. aureus DnaC helicase onto replicative primosomes, wherein said inhibitor inhibits bacterial growth.
8. The method of claim 7 , wherein said inhibitor is selected from the group consisting of a small molecule, a peptidomimetic compound, and a bacterial growth inhibitory bacteriophage polypeptide.
9. The method of claim 7 , wherein said inhibitor is a peptide synthesized by a recombinant expression system and purified, or artificially synthesized.
10. A method for inhibiting bacterial DNA synthesis, comprising contacting a bacterium in vitro with an effective amount of an inhibitor which decreases the activity of a polypeptide selected from the group consisting of:
a DnaI polypeptide comprising at least 50% identity to the amino acid sequence of SEQ IID NO: 2;
a DnaI polypeptide comprising fragments of the amino acid of SEQ ID NO: 2;
wherein said polypeptide has an activity selected from the group consisting of:
a) directly interacting with bacteriophage 77 ORF 104 protein or a DnaI-binding fragment thereof in a manner that results in at least 10 fold reduction of 3 H-thymidine incorporation in a bacterial DNA replication assay relative to 3 H-thymidine incorporation in an assay lacking bacteriophage 77 ORF 104 protein or a DnaI-binding fragment thereof;
b) directly interacting with bacteriophage 77 ORF 104 protein or a DnaI-binding fragment thereof in a manner that results in at least 10% inhibition of plasmid replication by bacteriophage 77 ORF 104 protein or a DnaI-binding fragment in a plasmid replication assay; and
c) aiding in the loading of S. aureus DnaC helicase onto replicative primosomes, wherein said inhibitor inhibits bacterial DNA synthesis.